InvestorsHub Logo
Followers 63
Posts 7611
Boards Moderated 1
Alias Born 01/02/2003

Re: Condor64 post# 221905

Wednesday, 10/30/2019 5:28:52 PM

Wednesday, October 30, 2019 5:28:52 PM

Post# of 430200
Condor...If a generic is marketed with a label, which purports to be a biosimilar to Vascepa, it must state on the label that the product is a treatment for CVD...any person, even though medically untrained, is aware that CVD is s chronic condition and must be treated for long periods of time and even for rest of a person's life...mentioning CVD on the generic product label(which it must have by law as a biosimilar)...makes this product an inducement for physicians to prescribe for a chronic condition and is therefore an infringement of Amarin patents....Lawyers can and will argue, but the facts in this case are clear.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News